Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel.

Modonutti D, Majdalany SE, Butaney M, Davis MJ, Corsi N, Sood A, Trinh QD, Cole AP, Rogers CG, Novara G, Abdollah F. Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel. Prostate. 2023 09; 83(13):1238-1246.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Humans
Male
Prognosis
Prostate-Specific Antigen
Taxoids
Treatment Outcome

authors with profiles

Akshay Sood

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support